Health Economy and Health Technology Assessment (HTA)

Petra Acher

Germany / DE

Health Economy and Health Technology Assessment (HTA)

Networker in health care politics as general manager Frankfurter Forum e.V.

Petra Acher graduated from the German Justus Liebig University, Giessen in agriculture with specialisation in animal production specialising in economics and animal health.

She began her career with Elanco, an animal health division of Eli Lilly & Co, working in market research, marketing and key account management, before she changed to the pharmaceutical department within Lilly Germany.  In various sales leadership assignments, she was responsible for market introduction of products in diabetes, CNS, cardiology, osteology and others. In this time she developed outstanding leadership and coaching skills specially in difficult people situations.

In 2007 she changed to corporate affairs becoming responsible to build and develop a new group of pharma key account management for the hospital business and later including contract business with sickness funds and other health care stakeholders. As director of key account management market access, she developed various successful market access strategies, becoming an expert and advisor within Lilly for various European and non-European countries (including China &Australia).

Since 2022 she is general manager of a non-profit organization, which answers principal questions on socio- and health politics.

Petra Acher is married and has 3 children.

Ernst Agneter, MD, PhD, MBA

Vienna / AT

Health Economy and Health Technology Assessment (HTA)

Head of Center for Pharmacological Medicine, Sigmund Freud Medical University Vienna

Managing Director, Agneter PharmaConsulting GmbH, Chairman of the Pharmig working group Health Economics & Reimbursement of Executive Board of Pharmig, Association of the Austrian Pharmaceutical Industry

Ernst Agneter is a specialist in pharmacology and toxicology. After receiving his PhD in 1989, he worked as a doctor of general medicine for the Ministry of Health in the area of drug approvals and as assistant at the Pharmacological Institute of the University of Vienna. In 2000, he obtained the teaching license for pharmacology and toxicology. In 2018 he was appointed to the Chair of Pharmacology of the Sigmund Freud Private University in Vienna. In addition, he holds a Master of Advanced Studies, a Master of Business Administration and an Examination in Wholesale Medicines and Poisons. Agneter served as Medical and Marketing Director in an international pharmaceutical company, as well as an external expert of the Federal Ministry for Social Security and Generations, and as a member of the EMEA experts nominated by Austria, as well as peer reviewers. In 2001, he founded the Agneter PharmaConsulting GmbH with a focus on the preparation of preclinical and clinical expert reports, evaluation of pharmaceuticals as well as pricing and reimbursement of proprietary medicinal products.

Lieven Annemans

Ghent / BEL

Health Economy and Health Technology Assessment (HTA)

Lieven Annemans is a Senior Professor of Health Economics at the Faculty of Medicine at Ghent University, Belgium. He has 20 years of experience in international health economics research. For many years he is a well sought expert consultant and lecturer in health technology assessment (HTA). He was advisor to the Belgian Minister of Health from 2001 to 2003 and president of the Flemish health council from 2003 to 2009. He is Past-President of ISPOR (International Society of PharmacoEconomics and Outcomes Research). He published more than 250 papers and several books on health economics and HTA.

Anna Bucsics MD

Vienna / AT

Health Economy and Health Technology Assessment (HTA)

Former department Head, Department of pharmaceutical Affairs, Federation of Austrian Social Insurance Institutions

MoCA Project Advisor since 2016. Lecturer at the Vienna School of clinical Research. Expert panel member of the Austrian Federal Administrative Court Member of the European Commission Experts Group on Rare Diseases. External Lecturer at the Department of Finance, University of Vienna

Advisor to the MEDEV Committee (an informal group of representatives and experts from payer institutions in Europe), Participation in European projects such as EUnetHTA, the High Level Pharmaceutical Forum, the Platform on Access to Medicines in Europe (in the working groups on access to biosimilars and orphan medicinal products), and Parallel Scientific Advice at EMA.

Department Head for the Main Association of Austrian Social Insurance Institutions (MAASSI) until the end of 2013. Previously, auditor for pharmaceutical expenditures at the Viennese Social Health Insurance and as pharmacological consultant for MAASSI

Training in internal medicine in Graz, diploma as a specialist for Pharmacology and Toxicology.

Medical degree from the Karl-Franzens-University of Graz, Austria, postgraduate research work in neuropharmacology at the Department of Experimental and Clinical Pharmacology.

Dávid Dankó

Hungary

Health Economy and Health Technology Assessment (HTA)

Dávid Dankó, PhD, MSc, is managing partner of Ideas & Solutions. He graduated in economics from Corvinus University of Budapest after scholarships in Sweden and Germany. He earned his PhD degree in 2012 with a thesis on long-term resource management in the pharmaceutical industry. Before 2010, he worked as Deputy Director of Reimbursement at the Hungarian National Health Insurance Fund. He has lectured at Vienna School of Clinical Research, Université Lyon 1 (EMAUD), Semmelweis University of Budapest, Eötvös Loránd University, and speaks regularly at international workshops and conferences on pharmaceutical and medical device reimbursement. He is also a regular invitee to international advisory boards and policy roundtables. Dávid works in English, German, Italian and Russian.

Prof. Dr. med. Dominique Dubois

Brussels / BE

Health Economy and Health Technology Assessment (HTA)

Dominique Dubois MD FBCPM FFPM

Physician Specialist in Pharmaceutical Medicine. Lecturer in Pharmacoeconomics & Patient Reported Outcomes Research. Vice-Chairman PHARMED PharmaTrain Centre of Excellence. Author of >50 publications in peer-reviewed journals. Specialty Chief Editor of Frontiers in Pharmaceutical Medicine and Outcomes Research.

Dominique contributed to the FDA PRO draft guidance, the EMEA reflection paper on HRQL measures, and an expert guidance report on coverage decision-making in orphan diseases. He was also largely instrumental in achieving a successful NICE Single Technology Appraisal.

Sebastian Iovan

Italy / IT

Health Economy and Health Technology Assessment (HTA)

Associate Vice President, Eli Lilly

Pricing, Reimbursement, Market Access Italy, CEE, Israel, Russia

Sebastian is a Medical Doctor with a Master of Science in Health Economics from Bocconi University Milan, Italy and an MBA from IE Business School Madrid, Spain. In his 15 years with Eli Lilly, Sebastian has been responsible for Pricing & Market Access in different regions around the world. He also led Global Market Access Group for Lilly Diabetes portfolio based out of Indianapolis.

In his recent role, he is leading Pricing, Reimbursement & Market Access for Italy, Central Eastern Europe, Israel & Russia based in Florence, Italy.

Jürgen Raths

Geneva / CH

Health Economy and Health Technology Assessment (HTA)

Dr. Raths studied medicine and dentistry at the Universities of Heidelberg, Bonn and Cologne. He obtained his Doctorate in Medicine at the University of Bonn. He is MD with 30 years of experience in the European and global pharma business, with positions held in clinical research, medical, marketing, sales and General Management in Europe and the USA. Jürgen served as CEO in assignments in public and private specialty pharma companies. Jürgen is Managing Director of Cordée Consulting in Geneva and supports innoplexus, a German-Indian Big Data and Artificial Intelligence company as Head of Life Sciences. He has leadership experience in: general management, company creation, M&A, change management and corporate restructuring situations, as well as in global business development.

MD Jörg Rustige, MD

Germany

Health Economy and Health Technology Assessment (HTA)

Jörg studied physics in Kiel and Hamburg, and worked several years as a physicist in the field of high energy particles. He also completed Medical School in Hamburg, and has been practising fo more than 15 years in university and academic teaching hospitals specializing in internal medicine, interventional cardiology, emergency medicine and intensive care. He participated in the design and conduct of clinical trials, and initiated one of the biggest real-life registries in myocardial infarction in Germany. Jörg has also decades of experience in the pharma industry in Europe and North America, being responsible at different stages in senior positions for medical affairs, medical information, clinical research in all phases, regulatory, quality assurance and basic research laboratories. Lately, he had supported European small pharma companies in Medical Affairs and Regulatory and he is now active with Cordée Consulting and VSCR.

MD Steffen Wahler, MD

Germany / DE

Health Economy and Health Technology Assessment (HTA)

Steffen is Managing Director of Hamburg-based St. Bernward Consulting. He has held leadership positions in German health insurance as well as in medical device and pharmaceutical industry. He served as director in the German pharma trade association and was in the curator-board of IQWiG and the HTA division of DIMDI, both German health care evaluation bodies. Steffen obtained his Doctorate in Medicine at the University of Rostock and specialized as Diabetologist. He earned degrees in economics at Universities of California and York/England as well as at INSEAD, France. He is regularly publishing in his and adjacent fields, like epidemiology and care organization research. He co-authored the German Health Economics guidelines (Hanover Consensus). In his 25 years in local and global health care.

Claudia Wild

Vienna / AT

Health Economy and Health Technology Assessment (HTA)

Director, Strategy and management
Head: Evaluation of medical procedures, European cooperation

Claudia Wild is Chief Executive Officer (CEO) of AIHTA GesmbH since 2020. Before she has been Director of the LBI-HTA since its establishment in 2006. From 1989-2006 she worked as a Senior Researcher at the Institute of Technology Assessment at the Austrian Academy of Sciences and helped developing the research field Health Technology Assessment in Austria. Prior to that, she was Research Associate on “media impact on cognitions” at the Institute for Communications and Political Science at the University of Nuernberg/Germany and worked as a freelancer on media impact research projects. She studied communications & psychology at the University of Vienna and political sciences at the Ohio University in Athens/Ohio/USA and completed her studies with a Graduation at the University of Vienna as Doctor of Philosophy in 1985. In 2009, she habilitated in social medicine (Medical University Graz) on the topic of “resource allocation in health-care systems”.